Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/288571
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis |
Autor: | Martínez-Bosch, Neus CSIC ORCID CVN; Cristóbal, Helena CSIC; Iglesias, Mar; Gironella, Meritxell; Barranco, Luis E.; Visa, Laura; Calafato, Domenico CSIC ORCID; Jiménez-Parrado, Silvia; Earl, Julie; Carrato, Alfredo; Manero-Rupérez, Noemí CSIC; Moreno-Estellés, Mireia CSIC ORCID; Morales, Albert CSIC ORCID; Guerra, Carmen CSIC; Navarro Medrano, Pilar CSIC ORCID; García de Frutos, Pablo CSIC ORCID | Palabras clave: | PDAC AXL Pancreas Biomarker Differential diagnosis |
Fecha de publicación: | ene-2022 | Editor: | Elsevier | Citación: | EBioMedicine 75: 103797 (2022) | Resumen: | Background: Early diagnosis is crucial for patients with pancreatic ductal adenocarcinoma (PDAC). The AXL receptor tyrosine kinase is proteolytically processed releasing a soluble form (sAXL) into the blood stream. Here we explore the use of sAXL as a biomarker for PDAC. Methods: AXL was analysed by immunohistochemistry in human pancreatic tissue samples. RNA expression analysis was performed using TCGA/GTEx databases. The plasma concentrations of sAXL, its ligand GAS6, and CA19-9 were studied in two independent cohorts, the HMar cohort (n = 59) and the HClinic cohort (n = 142), including healthy controls, chronic pancreatitis (CP) or PDAC patients, and in a familial PDAC cohort (n = 68). AXL expression and sAXL release were studied in PDAC cell lines and murine models. Findings: AXL is increased in PDAC and precursor lesions as compared to CP or controls. sAXL determined in plasma from two independent cohorts was significantly increased in the PDAC group as compared to healthy controls or CP patients. Patients with high levels of AXL have a lower overall survival. ROC analysis of the plasma levels of sAXL, GAS6, or CA19-9 in our cohorts revealed that sAXL outperformed CA19-9 for discriminating between CP and PDAC. Using both sAXL and CA19-9 increased the diagnostic value. These results were validated in murine models, showing increased sAXL specifically in animals developing PDAC but not those with precursor lesions or acinar tumours. | Versión del editor: | http://dx.doi.org/10.1016/j.ebiom.2021.103797 | URI: | http://hdl.handle.net/10261/288571 | DOI: | 10.1016/j.ebiom.2021.103797 | Identificadores: | doi: 10.1016/j.ebiom.2021.103797 e-issn: 2352-3964 |
Aparece en las colecciones: | (IIBB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
75sAXLinPDAC_EBioMedicine.pdf | 2,82 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
23
checked on 20-abr-2024
WEB OF SCIENCETM
Citations
20
checked on 24-feb-2024
Page view(s)
27
checked on 23-abr-2024
Download(s)
9
checked on 23-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons